“The iconic $1,000 genome is very close to a reality—at least in terms of reagent costs,” writes Eleanor Herriman, director of G2 Research and Analysis with Kennedy Information Inc., in a June 3, 2011, article for BNA’s Life Sciences Law & Industry Report. “It seems timely, then, to check in on whole genome screening (WGS), a technique predicted to significantly affect personalized therapeutics, diagnostics, clinical medicine, and even consumer behavior.”

Titled “Whole Genome Sequencing: A ‘PC-Like’ Revolution for Medicine, Pharmaceuticals, and Society?,” the article compares the personal computer revolution to the DNA sequencer market, which “deserves attention and consideration soon, because the exponential trajectory it will follow will leave those who wait far behind.”

Exponential leaps in sequencing have “brought us so rapidly to the brink of an inexpensive, widely available WGS tool,” Herriman asserts, quoting statistics such as “approximately 25,000 genomes will be sequenced in 2011, including low-coverage genomes.” Claiming that WGS “is on the brink of breaking through a number of barriers and advancing at warp speed,” Herriman concludes, “it is not often that we participate in technologic evolutions of this magnitude. Pharmaceutical and biotech companies that delve deeply into this movement, and stay close to the innovators, will be well positioned to capture some hitherto unimaginable opportunities in coming years.”